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Current methods of detecting hepatitis B virus (HBV) mutations are time consuming, labor intensive, and not suitable for screening large
numbers of samples. A multiplex real-time PCR approach presented in this article is a hepatitis B virus quantification method that employs the
SYBR Green I dye in conjunction with wild-type HBV sequence-specific locked nucleic acid (LNA) probes. The three short LNA probes
distinguished the wild-type strain or three groups of mutants (rt173, rt180/rt181, and rt202/rt204) depending on perfect-match hybrids or mismatch
within one template simultaneously. Primers labeled with quencher minimized the background signals. This sensitive approach could quantify 102
copies of HBV virus, and as low as 1% mutants among 104 copies of wild-type HBV could be identified. The technique is handy and convenient,
requiring only 3.5 h to analyze 30 hepatitis B surface antigen-positive serum samples. The HBV isolates were confirmed by direct sequencing. Our
data indicate that real-time PCR with SYBR Green I dye is a reliable, rapid, and convenient technique for HBV quantification. Furthermore, by
incorporating fluorescent LNA probes, this technique becomes handy in identifying and classifying mutations in the HBV polymerase gene.
Being sensitive, specific, accurate, rapid, and convenient in nature, this technique could be a suitable diagnostic tool with wide application
particularly in cases in which large volumes of clinical samples are handled.
© 2006 Elsevier Inc. All rights reserved.Keywords: HBV mutant; Locked nucleic acid; Multiplex real-time PCRHepatitis B virus (HBV) is a partially double-stranded DNA
molecule virus that replicates through an RNA intermediate by
reverse transcription [1]. The reverse transcriptase responsible
for this aspect of the replication cycle lacks proofreading
function and, therefore, single base substitutions to the genome
are common. Moreover, prolonged therapeutic interventions of
antiviral therapy with adefovir, emtricitabine, lamivudine, and/
or telbivudine result in drug-induced gene mutations, which
appear as drug resistance [2–8], and a number of mutations
affecting almost exclusively amino acids in the B domain of the
HBV polymerase (rtV173L, rtL180M, and rtA181TV in domain⁎ Corresponding author. Fax: +86 571 87217044.
E-mail address: chenzhi@zju.edu.cn (Z. Chen).
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doi:10.1016/j.ygeno.2006.07.011B and rtM204SV/I in domain C) have been described. Thus, the
ability to detect these mutants is essential to further our
understanding of the natural history of HBV and its response
to antiviral therapy and immunoprophylaxis.
The specificity of mutation detection in antisense oligo
(ASO) hybridization is based on the difference in melting
behavior of perfectly matched duplexes with the target probe
and single mismatches [9]. The greater the difference
between the melting temperature (Tm) of the matched versus
mismatched duplexes (ΔTm) is, the better the oligo probe
discriminating power is [9]. Since the stability difference
between a perfectly matched duplex and a mismatched
duplex can be as small as 0.5°C, the discrimination between
two DNA sequences that differ by only 1 base is difficult.
This ΔTm is dependent upon the length of the probe, the type
152 Z. Sun et al. / Genomics 89 (2007) 151–159of mismatch, and the neighboring nucleotides. The longer the
ASO probe, the smaller the effect of a single-base mismatch
on overall duplex stability. The differential stability of a
matched versus mismatched duplex is the main limitation of
the use of oligonucleotide hybridization for detection of
single base substitutions. Oligonucleotide probes containing
locked nucleic acid (LNA) residues have shown strong
affinity for their complementary targets [10]. Because of their
high thermal stability when hybridized to DNA, LNA can be
designed such that they have a shorter length while keeping a
high Tm, hence enabling probe hybridization to occur during
the PCR annealing step. Recently, several reports have
documented the high discriminatory power of oligonucleo-
tides containing LNA to differentiate between match and
mismatch duplexes [11–13]. Here, we describe a five-color
quadruplex real-time PCR platform for virus DNA quantifica-
tion and mutant identification based on SYBR Green I dye in
conjunction with LNA probes. The target DNA (164 bp)
within five mutants was amplified with quencher primers, and
wild/mutant sites assembled into three groups were discrimi-
nated with three LNA probes, respectively. The total viral
DNA level and wild-type proportion of total viral DNA were
calculated according to the relevant standard curves (SYBR
Green I dye for total viral DNA level, probes 173, 180, and
204 for wild-type proportions of sites rt173, rt180/181, and
rt202/204, respectively), while mutant proportions of total
viral DNA were assayed using wild-type probes compared to
total viral DNA level.Results
LNA probes for mutant detection
By incorporating LNA residues into synthetic oligonucleo-
tides, probes can be made shorter while maintaining a high
Tm, allowing several probes to hybridize on the same fragment
for a particular site discrimination assay. The probe hybridized
only to its complementary wild-type PCR products and not to
the mutant PCR products (Fig. 1A).Fig. 1. Diagrammatic representation of the oligonucleotides used in this study. (A) Sc
and orientations. 1, drug-resistant site rtV173L; 2, rtL180M; 3, rtA181V; 4, rtS202IG
mutagenesis and gene assembly PCR, e.g., primer in group G1 with G2 generates frag
within the rt173 mutation. The primers corresponding to G1–G8 are listed in TableMultiplex real-time PCR assay with LNA probes for the
detection of the mutant control plasmids
To assess the performance of probes containing LNA as tools
for multiple-site mutation discrimination in a five-color multi-
plex 5′-nuclease assay, we developed an assay for detection of
three groups of mutations involved in HBV drug resistance,
with respect to the antiviral drugs adefovir, emtricitabine,
lamivudine, telbivudine, etc. To demonstrate that the multicolor
assay specifically distinguishes the wild-type and three groups
of mutations, differentially labeled probes containing LNAwere
designed using the strategy described under Materials and
methods. The three probes were designed complementary to the
wild-type strain and labeled with 6-carboxy-4′, 5′-dichloro-
2′,7′-dimethoxy fluorescein (JOE) (rt173), Cy3 (rt180/rt181),
or Cy5 (rt202/rt204) (Table 1). Total PCR amplicon was
monitored by measuring the level of SYBR Green I
fluorescence. The background signal (relative fluorescence
units (RFUs)) of SYBR Green I dye generated by the primer
dimers or the hairpins was minimized with the use of Dabcyl-
labeled primer, and the signal value decreased to 0 RFU (Fig.
2A), while primers without any modification generated about
3500 RFUs of SYBR Green I signal in contrast with blank
control (0 RFUs) (Fig. 2B). Moreover, recombinant wild-type
plasmid was used as reference for standard curve calculations.
The sensitivity of quantification was increased 10-fold from 103
to 102 copies with the Ct value near 35 and R
2 >0.999 (Fig. 3).
After thermal cycling, the parameter values for the analysis
should be dye-specific. The baseline values for four fluorescent
dyes (SYBR Green I, JOE, Cy3, and Cy5) were selected as
automatic, and the threshold values of the dyes were adjusted
differently, from 0.05 to 0.18, with SYBR Green I dye the
highest and Cy3 the lowest. Therefore, the standard curves that
correspond to the four dyes were calculated automatically, with
the slope, intercept, and R2 given (Fig. 3). PCR efficiency was
confirmed by the automated method of serial dilutions and
calculated from the slope of each curve. Fluorescent SYBR
Green I generated the best result with a value of 99.9%, while
Cy3 had the worst, 102.1%. The Ct values gained from Cy3
were greater than the others in each concentration.hematic representation of primers and hybridization probes indicating positions
; 5, rtM204IV. (B) Schematic representation of primers used in the site-directed
ment fused with product of primer G5 with G8 to construct a fragment at 743 bp,
5.
Table 1
Oligonucleotides used in HBV mutant detection
Target Sequence 5′–3′ Position (nt) Product size (bp) Annealing temperature
H3U Dabcyl–TGTATTCCCATCCCATCATCCT 599–620 164 54.5°C
H3L GGCCCCCAATACCACATCA 762–744 55.1°C
173 JOE–TATGGGAGTGGG–BHQ1 639–650 65°C
180 Cy3–CGTTTCTCCTGGCTC–BHQ2 659–673 66°C
204 Cy5–CCATATAACTGAAA–BHQ3 742–729 65°C
Boldface indicates the LNA monomer.
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The multiplex real-time PCR approach detected as few as 102
copies of templates as shown in Fig. 3 and Table 2, withFig. 2. The background signal (relative fluorescence units (RFUs)) of SYBR Green I
were collected at the first cycle. (A) Background signal of SYBRGreen I dye was min
(red rectangle). (B) Primers without any modification generated about 3500 RFUs oR2 =0.999, at a reliable value of Ct <35, the same as the single-
plex PCR. The sensitivity for the wild-type HBV in this
analytical technique was 102 copies (Fig. 4A). More than 1%
mutants in a population of 108-104 copies of wild-type (rt173,dye generated by the primer dimers or the hairpins. All five fluorescent signals
imized with the use of Dabcyl-labeled primer, and the signal value decreased to 0
f SYBR Green I signal in contrast to blank control (0 RFUs) (red rectangle).
Fig. 3. Calculated curves based on four-color multiplex real-time PCR results of wild-type plasmid control from 102 to 108 copies with R2>0.99. Equations in the
upper right corner correspond to SYBR Green I dye, probe 173, probe 180, and probe 204 from the top down.
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The detection limit for the mutant type was derived from the
equation
total HBV ¼ wildQtype HBVþmutantQtype HBV:
From this equation the true detection limit of the mutant
HBV was determined indirectly from the wild-type signal
since our probes were designed to hybridize with the wild-
type DNA sequence. The technique (results not shown)
could detect as few as 75 copies of wild HBV (R2 =0.98);
however, we chose 102 (R2 =0.999) to achieve a standard
graphical interpretation of the data by regression analysis.
As seen in Table 2, we also found that to distinguish theTable 2
Total
copies
Ratio of mutant (rt173 or rt180/181 or rt202/204) plasmid control:
wild-type plasmid control
108 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
107 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
106 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
105 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
104 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
103 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
102 100:0 99:1 95:5 50:50 25:75 10:90 5:95 1:99 0:100
NTC NTC NTC NTC NTC NTC NTC NTC NTC NTC
Wild-type and mutant mixtures were used for sensitivity determination. The
template for the mutant with the rt173 or rt180/181 or rt202/204 mutation was
mixed with the template for the wild-type at a constant ratio in each dilution.
NTC, no-template control; boldface, cannot be detected or distinguished by any
reporter; boldface italic, detected but cannot be distinguished; italic, detected
and poorly distinguished; underlined, poorly detected and cannot be distin-
guished; all others were well detected and distinguished by all reporters.mutant-type HBV accurately from the wild-type and attain
high sensitivity, the concentration of the mutant type in the
samples had to exceed 100 copies. However, probe 180 had
a one- to threefold lower sensitivity than the others (data not
shown). All reactions were run in parallel.
Hepatitis B surface antigen (HBsAg)-positive serum sample
testing
Of the 30 HBsAg-positive samples, 3 (10%) were positive at
the rt180 or rt181 mutation (group B, resistant to lamivudine,
emtricitabine, or adefovir), 4 (13.33%) at the rt202 or rt204
mutation (group C, resistant to lamivudine, emtricitabine, or
telbivudine), and 5 (16.67%) at both the rt180/rt181 and the
rt202/rt204 mutation (group D, resistant to lamivudine, or
emtricitabine, or adefovir with telbivudine) (Table 3). More than
105 copies of total viral DNA with >85% of mutants were
screened in all isolates. Real-time PCR tracing plots are
presented in Fig. 5. Genomic sequences of clinical isolates
were confirmed by direct sequencing. The results showed that
the mutant types were the same as the real-time PCR assay
detected. The time required to perform this analysis consisted of
1 h for DNA isolation, 25 min for preparation of the reaction,
and 2 h for the sample run. To achieve a balance between
prevention of background signal (blank signal) and false
positives, an empirical thermocycling parameter of 35 cycles
was used.
Discussion
The emergence of HBV strains carrying mutants associated
with drug resistance is probably a result of the nature of the
Fig. 4. The real-time PCR tracing plots (log scale) of parts of wild-type/mutant mixing experiments. Green line for SYBR Green I signal, orange for probe 173, red for
probe 180, and pink for probe 204. (A) 102 copies of total viral DNAwith full percentage of mutant plasmid control (ID 10). (B) 108 copies of total viral DNAwith 99%
of wild-type plasmid control and 1% of mutant plasmid (ID 10). (C) 107 copies of total viral DNAwith 10% of mutant plasmid control (ID 2). (D) 107 copies of total
viral DNA with full percentage of mutant plasmid control (ID 2).
155Z. Sun et al. / Genomics 89 (2007) 151–159replication process that occurs via an RNA intermediate
requiring the activity of a reverse transcriptase [14]. This
replication process lacks 3′ exonuclease proofreading activity,
leading to misincorporation of bases. Natural mutants of HBV
occur at a relatively high frequency, estimated to be 10−5 nt
per year [15], compared to 10−9 nt per year for most other
DNA viruses [16]. The high mutation and replication rate
results in a viral population containing many variants with
single mutations, many of which are capable of producing
their own progeny. In addition, the nucleotide analogues, such
as lamivudine, emtricitabine, adefovir, and telbivudine, are
effective in inhibiting HBV replication during the viral DNA
synthesis through chain termination [2–5]. Drug-resistant
strains have been described after the therapeutic interventions
of antiviral therapy, with the appearance of HBV mutations in
the polymerase locus [6–8]. Thus, drug-resistant mutants
probably exist in the viral population even prior to the start of
antiviral therapy, albeit at a very low level [17]. In China,
however, there is no wide clinical use of antiviral drugs as yet,
with the exception of lamivudine; therefore virtually all
clinical isolates are resistant to only lamivudine. The detection
of the recognized and emerging HBV mutations is the key tounderstanding the natural history of HBV infections in
infected individuals and the documentation of the epidemio-
logical data. The studies facilitate clinicians and scientists by
shedding more light on the responses to therapeutic and
preventive interventions and overall management of HBV-
related diseases.
Previous studies of real-time PCR in HBV mutant
monitoring have shown the ability to detect minority
quasispecies at a level of 1 in 1000 by using primers in
which the relevant base pair mutation was at or near the
terminal 3′ base [18] and also the highly sensitive and easily
applicable assay INNO-LiPA [19]. Zhang et al. have shown
that hybridization probes with melting curve analysis
provided a reliable result, with 5% mutant among wild-type
virus [20]. However, there is no multiple-site identification
assay to date. This article describes a reliable, rapid, and
sensitive method for quantifying virus DNA and identifying
four nucleoside analogues associated antiviral/drug-resistance
mutations in the polymerase gene of HBV.
To prevent hybridizing competition, the accumulation of
PCR amplicons could be monitored by measurement of the
level of SYBR Green I fluorescence. One disadvantage of this
Table 3
Clinical isolates with (positive) or without (negative) mutants
Sample Mutant site Group
rt173 rt180/rt181 Rt202/rt204
1 – – – A
2 – – – A
3 – + + D
4 – + – B
5 – + – B
6 – – – A
7 – – + C
8 – – – A
9 – – + C
10 – – – A
11 – – – A
12 – – – A
13 – – – A
14 – + + D
15 – – – A
16 – – – A
17 – – – A
18 – – – A
19 – + + D
20 – + + D
21 – + – B
22 – – – A
23 – – – A
24 – – – A
25 – + + D
26 – – – A
27 – – – A
28 – – + C
29 – – + C
30 – – – A
+, positive; –, negative; A, no resistance; B, resistant to lamivudine,
emtricitabine, or adefovir; C, resistant to lamivudine, emtricitabine, or
telbivudine; D, resistant to lamivudine, or emtricitabine, or adefovir with
telbivudine.
156 Z. Sun et al. / Genomics 89 (2007) 151–159method is, however, that both primer dimers and hairpins can
raise the fluorescence signal of SYBR Green I, limiting
sensitivity. To solve this drawback, we developed a novel
method that attached the Dabcyl dye to the 5′-terminus of the
sense primer, which has more secondary structure. TheFig. 5. The real-time PCR tracing plots (log scale) of 30 HBsAg-positive clinical isola
and pink for probe 204.fluorescence of stain molecules that bind to the primer or its
dimer was quenched effectively. The chromogenic molecules
that bind at sites sufficiently remote from the quencher exhibit
fluorescence with chain elongation. Thus, the signal in
amplicon measurements more accurately indicated initial
target numbers, and the background fluorescence was reduced
[21]. Meanwhile, JOE, Cy3, and Cy5 reported three
identifying signals when probes matched with specific DNA
sequences within the wild-type strains. The combination of
these five fluorescence dyes could minimize the interference
of fluorescence resonance energy transfer with separated ex
\em filters of the 7500 system according to their spectra.
According to the fluorescence raw data (not shown), probes
173 and 204 were as sensitive as the SYBR Green I dye within
different thresholds, but probe 180 was less so. This suggests
that the target strands formed a secondary structure thereby
preventing hybridization to ssDNA since it was only seven
nucleotides from probe 173 to probe 180. Probe 204 also gave a
low signal when hybridized on the same strand as the other
probes; this may not be due to the structure prevention as
described by Jacobsen et al. [22] but to the decreasing 5′
exonuclease activity of Taq polymerase and the thermal
dynamics block. Thus, we have chosen SYBR Green I dye
instead of another probe and, furthermore, used probe 204 to
hybridize on the same template as the antisense primer, which
generated a reliable result.
LNA probes were 12–15 nt, with the same Tm and quench
efficiency as the TaqMan MGB but a single LNA mismatch
causing decreases in Tm values ranging from 12 (G/T) to 30°C
(A/A) [23]. The use of LNA probes results in an increased
melting temperature with a simultaneous increase in the ΔTm
between the perfectly matched and the mismatched targets (data
not shown), which made it possible to detect single base
substitutions. The precision of management of the annealing
temperature in the 9600 emulation of the 7500 system was
sufficient to enable us to distinguish samples differing by a
single base. However, since many nucleotide sequence varia-
tions occurred at the same site of probe binding, it was not
always possible to differentiate the genotype of any particular
virus with the probe alone.tes. Green line for SYBR Green I signal, orange for probe 173, red for probe 180,
Table 4
Variants associated with drug resistance corresponding to the amino acid and
DNA codon
Nucleic acid
analogue
Amino acids reverse transcriptase
V173L L180M A181V S202IG M204IV
Adefovir +
Emtricitabine + + +
Lamivudine + + +
Telbivudine +
DNA codons
Wild-type GTN CTN GCN TCN ATG
AGY
Mutant CTN
TTR
ATG GTN GGN ATH
ATH GTN
Boldface indicates the mutant site. + indicates that the variant was associated
with the drug resistance. N indicates A or T or C or G, R indicates A or G, H
indicates A or T or C, Y indicates C or T.
157Z. Sun et al. / Genomics 89 (2007) 151–159Moreover, it should be noted that the findings indicate that
our method is suitable for point mutation detection. However, it
remains to be determined whether the method is also suitable for
other clinically relevant mutations, such as deletions and
insertions within the viral genome.
This study shows that real-time PCR with SYBR Green I
dye is a reliable, rapid, and convenient technique for the
quantification of HBV mutants. Furthermore, by incorporat-
ing fluorescent LNA probes, this technique becomes handy
in identifying and classifying mutations in the polymerase
gene. Being sensitive, specific, accurate, rapid, and con-
venient in nature, this technique could be a suitable
diagnostic tool with wide application particularly in cases
in which large volumes of clinical samples are handled.
Furthermore, clinical application of this analytical method
could tremendously improve the management of patients withTable 5
Oligonucleotides used in the site-directed mutagenesis and gene-assembly PCR
Primer Sequence 5′–3′
ACU TGTTGCCCGTTTGTCCTCTACTTC
ACL CCGTGGGGGTTGCGTCAG
173ML GGCCCARTCCCATAGGAATCTT
173U TGGGCCTCAGTCCGTTTCTC
180ML CTGAGCCATGAGAAACGGACTGA
181ML CTGAACCAGGAGAAACGGACTGA
180181ML CTGAACCATGAGAAACGGACTGA
180MU GCTCAGTTTACTAGTGCCATTTGTTCA
181-180181MU GTTCA GTTTACTAGTGCCATTTGTTCA
202ML1 ATAGCCGAAAGCCAAACAGTGGG
204ML ATAGCTGAAAGCCAAACAGTGGG
202ML2-202204 ATAGAT GAAAGCCAAACAGTGGG
202MU1 CGGCTATATGGATGATGTGGTATTGGGG
202MU2 CATCTATATGGATGATGTGGTATTGGGG
204MU1 CAGCTATGTGGATGATGTGGTATTGGGG
204MU2 CAGCTATATHGATGATGTGGTATTGGGG
202204MU1 CATCTATATHGATGATGTGGTATTGGGG
202204MU2 CATCTATGTGGATGATGTGGTATTGGGG
Boldface indicates the mutant site. H indicates A or T or C, R indicates A or G. UnHBV-induced diseases. The technique could also be handy in
HBV genotyping.Materials and methods
Drug-resistant mutant sites of the HBV polymerase region are listed in Table
4 according to previous publications [6–8,24].
Design of PCR primers and LNA probes
The sequences of primers and LNA probes used in this study are listed in
Tables 1 and 5. Schematic representations of the locations and orientations of the
oligonucleotides used are shown in Figs. 1A and 1B. Primers and hybridization
probes were designed based on the nucleotide sequences of wild-type HBV
(GenBank Accession No. NC_003977 with nt 735 C changed to T) on the basis
that the wild-type HBV conserved sequence would increase the sensitivity and
specificity of our technique. Moreover, position 735 has a T, regardless of the
HBV type, in over 90% of the HBV sequences we analyzed from GenBank. The
probes containing LNA residues were designed such that the mutation site was
placed at a central location within the sequence of the oligonucleotide, with a Tm
of 65-66°C. The length was between 12 and 15 nucleotides with the mutation
site replaced by an LNA residue. The oligonucleotide probes contained between
4 and 8 LNA residues, which were introduced within the probe with a separation
of 1–3 nucleotides. The LNA probes were synthesized and labeled by Proligo
Co., Ltd. (Singapore). The other oligonucleotides were synthesized and labeled
by TaKaRa Biotechnology (Dalian) Co., Ltd. (China). The sequences of all the
oligonucleotides were analyzed for the absence of false priming sites and
formation of primers, probes, primer/probe hybrids, and secondary structures
and confirmed with the aid of the Lasergene sequence analysis software
(DNAStar, Inc., Madison, WI, USA).
Extraction of HBV DNA from sera
Thirty HBsAg-positive sera, uncharacterized for HBV mutants, were
obtained from First Affiliated Hospital of Zhejiang University. Code numbers
were used instead during this investigation. Permission to test the samples was
obtained from the Zhejiang University Conjoint Ethics Committee.
HBV DNAwas extracted from serum samples (100 μl) using the QIAquick
viral DNA extraction kit (Qiagen GmbH, Hilden, Germany). The DNA was
eluted in 100 μl of sterile dH2O and stored at −20°C until assayed.Position (nt) Product size (bp) Group
462–485 743 G1
1204–1187 G2
652–631 With ACU 191 G3
647–666 With ACL 558 G4
675–653 With ACU 214 G5
675–653 With ACU 214 G5
675–653 With ACU 214 G5
670–696 With ACL 535 G6
670–696 With ACL 535 G6
738–716 With ACU 277 G7
738–716 With ACU 277 G7
738–716 With ACU 277 G7
732–759 With ACL 473 G8
732–759 With ACL 473 G8
732–759 With ACL 473 G8
732–759 With ACL 473 G8
732–759 With ACL 473 G8
732–759 With ACL 473 G8
derline indicates complementary terminal regions.
Fig. 6. Detailed presentation of the recombinant HBV reference plasmid panel. Codon numbering is according to genotype A reverse transcriptase numbering. Three
periods indicate a gap introduced between codons 185 and 199; sequences in this gap are not relevant for the design of the assay. ID, clone identification number; wt,
wild type; H, A or T or C; Y, C or T.
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Recombinant plasmids containing inserts spanning the target region and
specific single-base mutations were constructed by overlap extension PCR.
Primers in groups G1/G3 and G2/G4, G1/G5 and G2/G6, as well as G1/G7 and
G2/G8 (Fig. 1B and Table 5) were used to amplify three clusters of
corresponding fragments for subsequent splicing by overlap extension PCR to
produce fragments of 743 bp for A-T cloning. The primers described previously
were designed to generate site-directed mutagenesis so that all corresponding
fragments contained a single-base substitution of rt173, rt180 and rt181, or rt202
and rt204. The DNA fragments were purified and cloned into the pMD18-T
vector (T-A cloning kit; TaKaRa Biotechnology (Dalian) Co., Ltd.). The
transformation of Escherichia coli with the recombinant plasmids was carried
out as instructed by the manufacturer (TaKaRa Biotechnology (Dalian) Co.,
Ltd.). The plasmids were extracted and purified by standard methods and
confirmed using an ABI Prism 3730 sequencer (Invitrogen Biotechnology
(Shanghai) Co., Ltd., China) (Fig. 6). The DNA concentration was determined
with a spectrophotometer at 260 nm, and the corresponding copy number of
plasmids was calculated. Plasmid serial dilutions ranging from 1×108 copies to
1 copy were then prepared.
Real-time PCR optimization
Plasmid controls were used as templates in this PCR assay to evaluate the
method and then followed with sera samples testing. The real-time PCR was
performed in a total volume of 30 μl containing 1 μl of DNA template, 0.3 μl of
1:1000×SYBR Green I and ROX dye (Molecular Probes, Inc., Eugene, OR,
USA), 1.5 U of Ex-Taq polymerase with 3 μl of 10×Mg2+-free buffer (TaKaRa
Biotechnology (Dalian) Co., Ltd.), 6 mMMg2+, 0.2 mM dNTPs, 9 pmol of each
primer, and 15 pmol of each probe. The 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA) performs product detection by monitoring
fluorescence changes in spectral windows with wavelengths ranging from 520 to
675 nm. Thermocycling parameters were as follows: 95°C for 20 s; then 40
cycles of 88°C for 10 s, 59°C for 10 s, and 72°C for 40 s to measure the
fluorescence signal; followed by the dissociation stage. Melting curves and
quantitative analysis of the data were performed using the 7500 System SDS
software v1.2.3 (Applied Biosystems). To determine the sensitivity of the
detection system for mutant HBV DNA among wild-type HBV DNA, mutant
and wild-type plasmid control DNAs were mixed at a constant ratio as shown in
Table 2. Full percentage wild-type plasmid control DNAs were used as
references for standard curve calculation in this sensitivity testing. SYBR Green
I signal was used to generate the curve to quantify the total viral DNA level.
LNA probe signals were used for establishing standard curves for wild-type viral
DNA calculations according to the three mutation sites. Moreover, the
quenching of the LNA probes’ fluorescence was used to distinguish the LNA
probes as to whether they were hybridized to the amplified viral DNA fragment
(wild-type) or not hybridized (mutant).
During the clinical sample testing, wild-type plasmid control DNAs,
diluted from 108 to 102 copies, were also used as references for standard curve
calculation in the procedure. The standard curve for total viral DNA
quantification was established according to the SYBR Green I signal, andLNA probe signals were used for establishing standard curves for wild-type
viral DNA level calculations for the three mutation sites. Thus, the mutant
viral DNA level was calculated according to the equation given above.
Therefore, the mutant/total viral DNA ratio was calculated by comparing the
mutant level to the total DNA level. In addition, no-template control and blank
control were also presented for negative controls.
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